558
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients

      research-article
      1 , 2 , 1 , 3 , 4 , 5 , 6 , 7 , 5 , 8 , 9 , 7 , 8 , 7 , 10 , 9 , 11 , 9 , 12 , 13 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 15 , 20 , 21 , 21 , 3 , 11 , 17 , 16 , 22 , 19 , 23 , 24 , 25 , 26 , 27 , 2 , 26 , 26 , 28 , 29 , 29 , 30 , 4 , 4 , 31 ,
      Journal of Neuroinflammation
      BioMed Central
      Neuromyelitis optica, Devic disease, Devic syndrome, longitudinally extensive transverse myelitis, recurrent optic neuritis, NMO-IgG, aquaporin-4 (AQP4) antibody, epidemiology, clinical features, magnetic resonance imaging, cerebrospinal fluid

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          The diagnostic and pathophysiological relevance of antibodies to aquaporin-4 (AQP4-Ab) in patients with neuromyelitis optica spectrum disorders (NMOSD) has been intensively studied. However, little is known so far about the clinical impact of AQP4-Ab seropositivity.

          Objective

          To analyse systematically the clinical and paraclinical features associated with NMO spectrum disorders in Caucasians in a stratified fashion according to the patients' AQP4-Ab serostatus.

          Methods

          Retrospective study of 175 Caucasian patients (AQP4-Ab positive in 78.3%).

          Results

          Seropositive patients were found to be predominantly female (p < 0.0003), to more often have signs of co-existing autoimmunity (p < 0.00001), and to experience more severe clinical attacks. A visual acuity of ≤ 0.1 during acute optic neuritis (ON) attacks was more frequent among seropositives (p < 0.002). Similarly, motor symptoms were more common in seropositive patients, the median Medical Research Council scale (MRC) grade worse, and MRC grades ≤ 2 more frequent, in particular if patients met the 2006 revised criteria (p < 0.005, p < 0.006 and p < 0.01, respectively), the total spinal cord lesion load was higher (p < 0.006), and lesions ≥ 6 vertebral segments as well as entire spinal cord involvement more frequent (p < 0.003 and p < 0.043). By contrast, bilateral ON at onset was more common in seronegatives (p < 0.007), as was simultaneous ON and myelitis (p < 0.001); accordingly, the time to diagnosis of NMO was shorter in the seronegative group (p < 0.029). The course of disease was more often monophasic in seronegatives (p < 0.008). Seropositives and seronegatives did not differ significantly with regard to age at onset, time to relapse, annualized relapse rates, outcome from relapse (complete, partial, no recovery), annualized EDSS increase, mortality rate, supratentorial brain lesions, brainstem lesions, history of carcinoma, frequency of preceding infections, oligoclonal bands, or CSF pleocytosis. Both the time to relapse and the time to diagnosis was longer if the disease started with ON (p < 0.002 and p < 0.013). Motor symptoms or tetraparesis at first myelitis and > 1 myelitis attacks in the first year were identified as possible predictors of a worse outcome.

          Conclusion

          This study provides an overview of the clinical and paraclinical features of NMOSD in Caucasians and demonstrates a number of distinct disease characteristics in seropositive and seronegative patients.

          Related collections

          Most cited references69

          • Record: found
          • Abstract: found
          • Article: not found

          A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis.

          Neuromyelitis optica is an inflammatory demyelinating disease with generally poor prognosis that selectively targets optic nerves and spinal cord. It is commonly misdiagnosed as multiple sclerosis. Neither disease has a distinguishing biomarker, but optimum treatments differ. The relation of neuromyelitis optica to optic-spinal multiple sclerosis in Asia is uncertain. We assessed the capacity of a putative marker for neuromyelitis optica (NMO-IgG) to distinguish neuromyelitis optica and related disorders from multiple sclerosis. Indirect immunofluorescence with a composite substrate of mouse tissues identified a distinctive NMO-IgG staining pattern, which we characterised further by dual immunostaining. We tested masked serum samples from 102 North American patients with neuromyelitis optica or with syndromes that suggest high risk of the disorder, and 12 Japanese patients with optic-spinal multiple sclerosis. Control patients had multiple sclerosis, other myelopathies, optic neuropathies, and miscellaneous disorders. We also established clinical diagnoses for 14 patients incidentally shown to have NMO-IgG among 85000 tested for suspected paraneoplastic autoimmunity. NMO-IgG outlines CNS microvessels, pia, subpia, and Virchow-Robin space. It partly colocalises with laminin. Sensitivity and specificity were 73% (95% CI 60-86) and 91% (79-100) for neuromyelitis optica and 58% (30-86) and 100% (66-100) for optic-spinal multiple sclerosis. NMO-IgG was detected in half of patients with high-risk syndromes. Of 14 seropositive cases identified incidentally, 12 had neuromyelitis optica or a high-risk syndrome for the disease. NMO-IgG is a specific marker autoantibody of neuromyelitis optica and binds at or near the blood-brain barrier. It distinguishes neuromyelitis optica from multiple sclerosis. Asian optic-spinal multiple sclerosis seems to be the same as neuromyelitis optica.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            The spectrum of neuromyelitis optica.

            Neuromyelitis optica (also known as Devic's disease) is an idiopathic, severe, demyelinating disease of the central nervous system that preferentially affects the optic nerve and spinal cord. Neuromyelitis optica has a worldwide distribution, poor prognosis, and has long been thought of as a variant of multiple sclerosis; however, clinical, laboratory, immunological, and pathological characteristics that distinguish it from multiple sclerosis are now recognised. The presence of a highly specific serum autoantibody marker (NMO-IgG) further differentiates neuromyelitis optica from multiple sclerosis and has helped to define a neuromyelitis optica spectrum of disorders. NMO-IgG reacts with the water channel aquaporin 4. Data suggest that autoantibodies to aquaporin 4 derived from peripheral B cells cause the activation of complement, inflammatory demyelination, and necrosis that is seen in neuromyelitis optica. The knowledge gained from further assessment of the exact role of NMO-IgG in the pathogenesis of neuromyelitis optica will provide a foundation for rational therapeutic trials for this rapidly disabling disease.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Natural history of multiple sclerosis: a unifying concept.

              Multiple sclerosis can follow very different patterns of evolution and variable rates of disability accumulation. This raises the issue whether it represents one or several distinct diseases. We assessed demographic and clinical characteristics in 1844 patients with multiple sclerosis that we categorized according to the classification of Lublin and Reingold (1996) into 1066 (58%) relapsing-remitting, 496 (27%) secondary progressive, 109 (6%) progressive relapsing and 173 (9%) primary progressive cases of multiple sclerosis. Relapsing-remitting and secondary progressive cases shared similar age at disease onset (median = 28.7 versus 29.5 years; P = 0.21), initial symptoms of the relapsing-remitting phase, degree of recovery from the first neurological episode, and time from the first to the second episode. By contrast, disease duration was twice as long in secondary progressive than in relapsing-remitting cases (mean +/- SD = 17.6 +/- 9.6 versus 8.7 +/- 8.6 years; P < 0.001). Progressive relapsing and primary progressive cases were essentially similar in their clinical characteristics. In patients experiencing a progressive course, median age at onset of progressive phase was similar in secondary progressive cases and in cases who were progressive from onset (39.1 versus 40.1 years; P = 0.47). The proportion of cases with superimposed relapses during progression was approximately 40% in both categories. Finally, the 1562 patients with an exacerbating-remitting initial course and the 282 patients with a progressive initial course of the disease were essentially similar with respect to the time course of disability accumulation from assignment to a given disability score, and the age at assignment of disability landmarks. These observational data suggest that the clinical phenotype and course of multiple sclerosis are age dependent. Relapsing-remitting disease can be regarded as multiple sclerosis in which insufficient time has elapsed for the conversion to secondary progression; secondary progressive forms as relapsing-remitting multiple sclerosis that has 'grown older'; and progressive from onset cases as multiple sclerosis 'amputated' from the usual preceding relapsing-remitting phase. Times to reach disability milestones, and ages at which these landmarks are reached, follow a predefined schedule not obviously influenced by relapses, whenever they may occur, or by the initial course of the disease, whatever its phenotype. This leads to a unifying concept of the disease in which primary and secondary progression might be regarded as essentially similar. From the clinical and statistical positions, multiple sclerosis might be considered as one disease with different clinical phenotypes rather than an entity encompassing several distinct diseases-the position of complexity rather than true heterogeneity.
                Bookmark

                Author and article information

                Journal
                J Neuroinflammation
                Journal of Neuroinflammation
                BioMed Central
                1742-2094
                2012
                19 January 2012
                : 9
                : 14
                Affiliations
                [1 ]Division of Molecular Neuroimmunology, Department of Neurology, University of Heidelberg, Heidelberg, Germany
                [2 ]Department of Neurology, Charité - University Medicine Berlin, Berlin, Germany
                [3 ]Institute of Clinical Neuroimmunology, Ludwig Maximilian University Munich, Munich, Germany
                [4 ]Department of Neurology, Heinrich Heine University, Düsseldorf, Germany
                [5 ]Department of Neurology, University of Würzburg, Würzburg, Germany
                [6 ]Department of Neurology, University of Regensburg, Regensburg, Germany
                [7 ]Department of Neurology, St. Josef-Hospital, Ruhr-University Bochum, Bochum, Germany
                [8 ]Department of Neurology, Klinikum rechts der Isar, Technische Universität München, Germany
                [9 ]Department of Neurology, University of Ulm, Ulm, Germany
                [10 ]Department of Neurology, Friedrich Alexander University, Erlangen, Germany
                [11 ]Department of Neurology, Goethe University Frankfurt, Frankfurt, Germany
                [12 ]Department of Neurology, University of Tübingen, Tübingen, Germany
                [13 ]Department of Neurology, Hannover Medical School, Hannover, Germany
                [14 ]Department of Neurology, University of Münster, Münster, Germany
                [15 ]Department of Neurology, Hospital Martha-Maria Halle, Halle, Germany
                [16 ]Department of Neurology, and Institute for Neuroimmunology and Clinical Multiple Sclerosis Research, University Medical Center, Hamburg, Germany
                [17 ]Department of Neurology, Asklepios Hospital Teupitz, Teupitz, Germany
                [18 ]Department of Neurology, Kliniken Landkreis Sigmaringen GmbH, Sigmaringen, Germany
                [19 ]Department of Neurology, University of Leipzig, Leipzig, Germany
                [20 ]Department of Neurology, Klinikum Görlitz, Görlitz, Germany
                [21 ]Department of Neurology, Klinikum Bayreuth, Bayreuth, Germany
                [22 ]Institute of Experimental Neuroimmunology, affiliated to Euroimmun Lübeck, Lübeck, Germany
                [23 ]Department of Neurology, Dietrich Bonhoeffer Klinikum Neubrandenburg, Neubrandenburg, Germany
                [24 ]Department of Neurology, Rheinhessen-Fachklinik Alzey, Alzey, Germany
                [25 ]Department of Neurology, Dr. Horst Schmidt Hospital Wiesbaden, Wiesbaden, Germany
                [26 ]Department of Neurology, University of Rostock, Rostock, Germany
                [27 ]Department of Neurology, Klinikum Dortmund, Dortmund, Germany
                [28 ]Department of Neuropathology, University of Göttingen, Göttingen, Germany
                [29 ]Department of Neurology, Hanse-Klinikum Stralsund, Stralsund, Germany
                [30 ]Department of Neurology, Helios Vogtland-Klinikum Plauen, Plauen, Germany
                [31 ]Neurocure, Charité - University Medicine Berlin, Berlin, Germany
                Article
                1742-2094-9-14
                10.1186/1742-2094-9-14
                3283476
                22260418
                3eea778e-858e-41f3-a00c-ccc464555293
                Copyright ©2012 Jarius et al; licensee BioMed Central Ltd.

                This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

                History
                : 23 September 2011
                : 19 January 2012
                Categories
                Research

                Neurosciences
                clinical features,aquaporin-4 (aqp4) antibody,devic disease,devic syndrome,magnetic resonance imaging,longitudinally extensive transverse myelitis,cerebrospinal fluid,recurrent optic neuritis,neuromyelitis optica,epidemiology,nmo-igg

                Comments

                Comment on this article